Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy by Nasir, Nosheen et al.
eCommons@AKU 
Section of Internal Medicine Department of Medicine 
9-2019 
Risk factors for mortality of patients with ceftriaxone resistant E. 
coli bacteremia receiving carbapenem versus beta lactam/beta 
lactamase inhibitor therapy 
Nosheen Nasir 
Sara Ahmed 
, Samrah Razi 
Safia Awan 
Syed Faisal Mahmood 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_intern_med 
 Part of the Internal Medicine Commons 
Nasir et al. BMC Res Notes          (2019) 12:611  
https://doi.org/10.1186/s13104-019-4648-7
RESEARCH NOTE
Risk factors for mortality of patients 
with ceftriaxone resistant E. coli bacteremia 
receiving carbapenem versus beta lactam/beta 
lactamase inhibitor therapy
Nosheen Nasir1* , Sara Ahmed3, Samrah Razi2, Safia Awan3 and Syed Faisal Mahmood1
Abstract 
Objective: Extended spectrum β-lactamases (ESBL) producing Enterobacteriaceae predominantly E. coli and K. pneu-
moniae bacteremia have limited treatment options and high mortality. The objective was to determine the risk factors 
for in-hospital mortality particularly treatment with carbapenem versus beta lactam/beta lactamase combination (BL/
BLI) in patients with ceftriaxone resistant E. coli bacteremia. A retrospective cohort study was conducted at the Aga 
Khan University, Karachi, Pakistan. Adult patients with sepsis and monomicrobial ceftriaxone resistant E. coli bactere-
mia were enrolled. Factors associated with mortality in patients were determined using logistic regression analysis.
Results: Mortality rate was 37% in those empirically treated with carbapenem compared to 20% treated with BL/BLI 
combination therapy (p-value: 0.012) and was 21% in those treated with a carbapenem compared to 13% in patients 
definitively treated with BL/BLI combination therapy (p-value: 0.152). In multivariable logistic regression analysis, only 
Pitt bacteremia score of ≥ four was significantly associated with mortality (OR: 7.7 CI 2.6–22.8) while a urinary source 
of bacteremia was protective (OR: 0.26 CI 0.11–0.58). In-hospital mortality in patients with Ceftriaxone resistant E. coli 
bacteremia did not differ in patients treated with either a carbapenem or BL/BLI combination. However, Pitt bactere-
mia score of ≥ 4 was strongly associated with mortality.
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Introduction
Escherichia coli is a leading cause of intra-abdominal, 
urinary tract, and bloodstream infections encoun-
tered in routine clinical practice [1]. It is a recognized 
pathogen for causing both community acquired and 
nosocomially acquired infections [1, 2]. Over the past 
two decades, antibiotic-resistant strains that produce 
extended spectrum β-lactamases (ESBL) have emerged 
among the Enterobacteriaceae, predominantly in E. coli 
and Klebsiella pneumoniae [2–4]. ESBLs are a group of 
hydrolyzing enzymes that provide resistance to third gen-
eration cephalosporins and aztreonam, but can in turn be 
hydrolyzed by clavulanic acid [5]. Several epidemiologi-
cal studies have investigated the prevalence of ESBLs and 
their clinical impact [2, 3, 6]. There is considerable geo-
graphic variability in the prevalence of ESBLs with the 
prevalence being highest in from Latin America and Asia 
Pacific region followed by Europe and North America [4]. 
In a recently conducted meta-analysis from Pakistan, the 
pooled prevalence of ESBL producing Enterobacteriaceae 
was reported to be 40% [7]. This is similar to proportions 
reported from neighbouring countries of China [8] and 
India [9] and considerably higher than US and developed 
countries from Europe [5]. Hence, Pakistan is a coun-
try with high endemicity of community acquired ESBL 
producing Enterobacteriaceae with major public health 
implications [10, 11].
Since ESBL-producing organisms are frequently resist-
ant to multiple antimicrobial agents therapeutic options 
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for these infections are severely limited [12]. Moreo-
ver infections caused by ESBL producing organisms 
have been associated with high morbidity and mortality 
[13]. Studies have shown high Pitt bacteremia score and 
Charlson co-morbidity index to be predictive of death 
in patients with sepsis secondary to ESBL producing 
organisms [14]. Bacteremia with ESBL producing organ-
isms has been associated with a delay in the initiation of 
appropriate treatment regimens and leads to an increase 
in the hospital length of stay and cost of overall treatment 
[14, 15]. Carbapenems have been considered as drugs 
of choice for treating severe infections caused by ESBL 
producing Enterobacteriaceae as they are not affected 
by ESBLs in vitro and clinical efficacy has been demon-
strated in several observational studies as well as clinical 
trials [5, 16, 17]. A large multi-country open label non-
inferiority randomized controlled (MERINO) trial which 
compared piperacillin tazobactam with meropenem as 
definitive treatment for Ceftriaxone resistant E. coli or 
K. pneumoniae bloodstream infection found significantly 
higher long term mortality in patients randomized to 
piperacillin tazobactam arm [16]. However, prolonged 
use of carbapenems places the community at risk of 
development of carbapenem resistance due to antibiotic 
selection pressure [18]. Thus it is imperative to find alter-
natives for treatment. Beta lactam/beta lactam inhibi-
tor combinations (BL/BLI) have been widely studied 
both as empiric and definitive choice of antibiotics and 
while some studies have reported no difference in clini-
cal outcomes with use of BL/BLI combination compared 
to carbapenem [19]; pooled data from meta-analysis have 
recommended their use for only clinically stable patients 
with urinary tract infections as the source [17].
Existing studies from Pakistan have shown that ESBL 
producing strains of Enterobacteriaceae show greater 
than 90 percent susceptibility for BL/BLI and hence may 
be an effective alternative [10, 11]. Carbapenem use has 
severe cost constraints in a low middle country like Paki-
stan and is reserved for very severe infections. Despite 
the high endemicity of ESBL producing organisms, data 
on risk factors for mortality and the optimal choice of 
antibiotic therapy is lacking. Our study aims to deter-
mine the risk factors for in-hospital mortality in patients 
with ESBL E. coli bacteremia using ceftriaxone resistance 
as a marker of ESBL presence; with emphasis on differ-
ence in outcome when patients were treated with a car-
bapenem compared to beta lactam/beta lactam inhibitor 
combination at a tertiary care hospital in Pakistan.
Main text
Methods
A retrospective cohort study was conducted at the Aga 
Khan University (AKU) Hospital in Karachi, Pakistan on 
patients admitted between January 2015 to December 
2017. All adult patients with age greater than or equal to 
18 years admitted with sepsis (based on established cri-
teria) [20] and found to have monomicrobial ceftriaxone 
resistant E. coli bacteremia were included in the study. 
Patients were identified from the hospital information 
management system.
Data collected from medical records for all patients 
included age, sex, nosocomial or community-onset acqui-
sition, type and severity of underlying conditions using 
the Charlson comorbidity index, source of bloodstream 
infection (BSI) according to clinical and microbiological 
data, Pitt bacteremia score, antimicrobial therapy, in-hos-
pital mortality, and length of stay after BSI. The outcome 
measure was ‘In-hospital mortality’ and was defined 
as death due to all causes during same hospitalization. 
Antimicrobial therapy administered before susceptibility 
results were available was considered empirical and ther-
apy administered afterwards was considered definitive.
Frequency and percentages were used to describe cat-
egorical variables and comparison between variables was 
determined using Chi square test or Fischer exact test 
where appropriate. p-value of < 0.05 was considered sig-
nificant. Univariable analyses were performed to examine 
the effect of each variable on the in-hospital mortality. In 
univariable analysis; p-value < 0.15 was used as the level 
of significance in order not to exclude important variables 
from the model. Odds ratios (OR) and their 95% confi-
dence intervals (CI) were estimated using logistic regres-
sion, with in-hospital mortality as an outcome. Data was 
analyzed using SPSS version 16.0.
This study was conducted after receiving exemption 
from ethical approval from Aga Khan University Ethical 
Review Committee (2734-MED-ERC-13).
Results
Out of a total of the 295 patients that were included, 47% 
were males while 53% were females. The mean age of 
the patients was 57.71 years (SD: 17.16): Of the patients 
who died, the mean age was 55.3  years (SD: 17.9) years 
compared to 60.1 (SD: 16.5) years for those who sur-
vived (p-value: 0.046). The overall in-hospital mortality in 
patients with Ceftriaxone resistant E. coli bacteremia was 
21%. The mean length of stay was 11.3 days (SD: 12.5) in 
those who died compared to 6.8 days (SD: 5.68) in those 
who survived (p-value < 0.001) (Table 1).
In the univariate analysis to determine association 
between choice of empirical treatment and mortality; 
out of 60 patients who died, n = 20 had received a car-
bapenem and n = 31 had received a BL/BLI combina-
tion therapy. Mortality rate was 37% in those treated 
with carbapenem compared to 20% in patients empiri-
cally treated with BL/BLI combination therapy (p-value: 
Page 3 of 5Nasir et al. BMC Res Notes          (2019) 12:611 
0.012). For definitive treatment; n = 36 received a car-
bapenem whereas n = 21 received BL/BLI combination 
therapy among those who died. Mortality rate was 21% 
in those treated with a carbapenem compared to 13% in 
patients definitively treated with BL/BLI combination 
therapy (p-value: 0.152). Other variables found to be sig-
nificantly associated with mortality included increasing 
mean Charlson comorbidity index and increasing Pitt 
bacteremia score (Table 1).
However, in multivariable logistic regression analysis; 
a Pitt bacteremia score of greater than or equal to 4 was 
significantly associated with mortality (OR: 16.8 CI 7.47–
38.0) while presence of urinary tract infection being the 
source of bacteremia was protective (OR: 0.33 (CI 0.15–
0.73)) after adjusting for confounding from Charlson 
comorbidity index of greater than or equal to 3 (Table 2). 
Neither the empirical nor definitive antibiotic therapy 
with carbapenem versus BL/BLI combination therapy 
was significantly associated with in-hospital mortality.
Discussion
Empiric and definitive choice of antimicrobial therapy 
for ESBL producing Enterobacteriaceae has been subject 
of debate since a long time because of the implications 
of using carbapenem for ESBL infections which while 
effective has the potential for promoting carbapenem 
resistance [18]. Our study did not show an association 
of mortality with use of either a carbapenem or a BL/
BLI combination treatment in ceftriaxone resistant E. 
coli bacteremia whether it was used empirically or defini-
tively. These findings are similar to a post hoc analysis of 
prospective cohort conducted by Rodriguez-Bano et  al. 
[19] where neither carbapenem nor BL/BLI combination 
Table 1 Comparison of demographics and clinical features of patients with ceftriaxone resistant E. coli bacteremia who 
died compared to those who survived
a Empirical group includes only those patients who had been given either a carbapenem or BL/BLI combination treatment empirically
b Definitive group includes only those patients who had been given either a carbapenem or BL/BLI combination treatment as definitive treatment
Patient characteristics Died (n = 62) Recovered (n = 235) p-value
Age (mean ± SD) 55.28 ± 17.87 60.14 ± 16.46 0.046
Gender
 Male 34 106 0.172
 Female 28 129
Charlson comorbidity index (CCI), mean (SD) 2.98 (2.12) 1.93 (1.73) < 0.001
Pitt bacteremia score, median (IQR) 3 (4) 1 (2) < 0.001
Site of infection
 Intra-abdominal 24 44 < 0.001
 UTI 24 171
 CLABSI 4 4
 Gut translocation 4 5
 Source unclear 6 11
Empirical  antibioticsa 0.012
 Carbapenem 20 33
 BL/BLI 31 121
Definitive  antibioticsb
 Carbapenem 36 138 0.152
 BL/BLI 12 77
Length of stay (mean ± SD) 11.27 ± 12.46 6.82 ± 5.68 < 0.001
Table 2 Multivariable analysis showing factors associated 
with  in-hospital mortality in  patients with  Ceftriaxone 
resistant E. coli bacteremia
Variables aOdd ratio (95% CI) p-value
Pitt bacteremia score
 < 4 (Ref ) 1.0 < 0.001
 ≥ 4 16.85 (7.47–38.0)
Source of infection
 Intra-abdominal (Ref ) 1.0 0.002
 Urinary tract infection 0.33 (0.15–0.73) 0.006
 CLABSI 3.03 (0.62–14.66) 0.16
 Gut translocation 2.97 (0.50–17.43) 0.22
 Source unclear 1.07 (0.28–4.03) 0.91
Charlson comorbidity index score
 < 3 (Ref ) 1.0 0.055
 ≥ 3 1.98 (0.98–3.97)
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influenced mortality or hospital length of stay. How-
ever, the recently conducted multi-country open label 
non-inferiority randomized controlled (MERINO) trial 
which compared piperacillin tazobactam with mero-
penem as definitive treatment for Ceftriaxone resistant 
E. coli or K. pneumoniae bloodstream infection found 
significantly higher long term mortality in patients ran-
domized to piperacillin tazobactam arm and concluded 
that piperacillin tazobactam was not non-inferior (risk 
difference: 8.6%; p = 0.90). The authors therefore rec-
ommended avoiding use of this combination for Ceftri-
axone resistant bloodstream infections [16]. However, 
the trial had several limitations owing to its pragmatic 
design with crossover in both arms and that the cause of 
30-day mortality was unrelated to infection. Despite the 
criticism, the results were quite robust for the conclu-
sion [21]. Given the conclusion of this trial, the concern 
for increased carbapenem resistance with increasing use 
has left many experts to consider piperacillin tazobactam 
for less severe infections with ESBL producing entero-
bacteriaceae [21]. Despite this, similar to the MERINO 
trial, our study showed that the short-term outcomes (i.e. 
inpatient mortality) is similar for both carbapenems and 
BL/BLI combinations in ceftriaxone resistant Enterobac-
teriaceae. Our study was however not designed to look at 
the long term effects between the two regimens, includ-
ing the outcomes post discharge. As for other compari-
sons between both antibiotics as empirical therapy, there 
has been a systematic review and meta-analysis of non-
randomized studies which concluded that carbapenems 
should be given preference as drug of choice in patients 
with ESBL-producing Enterobacteriaceae bloodstream 
infections [17]. However, there was substantial clini-
cal and statistical heterogeneity in the studies included 
in this review and a more recent review conducted by 
Sfeir et al. [22] in 2018 have not found any difference in 
30-day mortality with use of either carbapenem or BL/
BLI combination. Comparison studies for appropriate 
choice of antibiotic for ESBL producing Enterobacte-
riaceae bacteremia are lacking from South Asian region 
which differs from the west in terms of geographical and 
economic diversity. A resource poor country like ours 
where carbapenem use has severe cost implications and 
is considered to be one of the last resort antibiotics, it is 
imperative to determine which antibiotic is better and we 
recommend future randomized controlled trials in this 
region based on our results.
Several predictors of mortality; apart from choice of 
antibiotics; have been identified in various studies for 
ESBL Enterobacteriaceae bloodstream infections. These 
include high Charlson comorbidity index, high Pitt bac-
teremia scores and source of bloodstream infection other 
than urinary tract [13, 14, 23]. In our study also we found 
significant association of Pitt bacteremia score of greater 
than 4 to be significantly associated with in-hospital mor-
tality in patients with ceftriaxone resistant E. coli bac-
teremia. Moreover, similar to findings of other studies, 
presence of urinary tract infection was favourable.
Conclusion
In conclusion, our study shows that there was no differ-
ence in in-hospital mortality in patients with ceftriaxone 
resistant E. coli bacteremia in patients treated with either 
a carbapenem or BL/BLI combination whether empiri-
cally or definitively. However, Pitt bacteremia score of 
greater than or equal to 4 was strongly associated with 
mortality while urinary tract as site of infection was pro-
tective. We recommend randomized controlled trials for 
further delineating choice of appropriate antibiotic in our 
resource poor region.
Limitations
There are several limitations of our study. Firstly, we have 
used Ceftriaxone resistance as a marker of ESBL presence 
and we do not have genotypic and MIC data for our iso-
lates. However, the study is intended to guide in real life 
scenarios encountered in clinical practice in our setting 
where molecular studies are not widely available. More-
over, large pragmatic trial has also utilized ceftriaxone 
resistance as surrogate marker for better feasibility [16]. 
Secondly, our study is a single center study and hence the 
generalizability may be limited to our region. Similarly, 
the lack of difference in mortality, especially between the 
two treatment regimens, may have been due to the small 
sample size.
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